The role of adiponectin in cardiovascular disease

Cardiovasc Pathol. 2023 May-Jun:64:107514. doi: 10.1016/j.carpath.2022.107514. Epub 2023 Jan 10.

Abstract

Cardiovascular disease (CVD) is a common disease that seriously threatens the health of human beings, especially middle-aged and elderly people over 50 years old. It has the characteristics of high prevalence, high disability rate and high mortality rate. Previous studies have shown that adiponectin has therapeutic effects on a variety of CVDs. As a key adipokine, adiponectin, is an abundant peptide-regulated hormone that is mainly released by adipocytes and cardiomyocytes, as well as endothelial and skeletal cells. Adiponectin can protect against CVD by improving lipid metabolism, protecting vascular endothelial cells and inhibiting foam cell formation and vascular smooth muscle cell proliferation. Further investigation of the molecular and cellular mechanisms underlying the adiponectin system may provide new ideas for the treatment of CVD. Herein, this review aims to describe the structure and function of adiponectin and adiponectin receptors, introduce the function of adiponectin in the protection of cardiovascular disease and analyze the potential use and clinical significance of this hormone in the protection and treatment of cardiovascular disease, which shows that adiponectin can be expected to become a new therapeutic target and biomarker for the diagnosis and treatment of CVD.

Keywords: Adiponectin; Cardiovascular disease; Therapeutic strategy.

Publication types

  • Review

MeSH terms

  • Adipocytes
  • Adiponectin / metabolism
  • Aged
  • Biomarkers
  • Cardiovascular Diseases*
  • Endothelial Cells / metabolism
  • Humans
  • Middle Aged

Substances

  • Adiponectin
  • Biomarkers
  • ADIPOQ protein, human